Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC with Fanconi Anemia. The main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), could be an effective treatment option to control cancer for patients with FA - HNSCC.

Trial Details

NCT ID
NCT06648096
Phase
PHASE1 / PHASE2
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Afatinib
Locations (sample)
  • Hanover, Germany|52.37052,9.73322
  • Barcelona, Catalonia, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Written informed consent according to local guidelines, must be signed and dated by the participant and investigator prior to performing any protoc…
  • Patient is ≥ 18 years of age.
  • Confirmed diagnosis of Fanconi anemia.
  • Histologically or cytologically confirmed unresectable or locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypophary…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →